Several randomized controlled trials (RCTs) were conducted to investigate the effect of remdesivir for patients with COVID-19, but their results were conflicting. Thus, we conducted a network meta-analysis comparing the rate of clinical improvement among patients with COVID-19 who received 5-day course of remdesivir versus 10-day course of remdesivir versus standard care. Our network meta-analysis of 4 randomized controlled trials demonstrated that the rate of clinical improvement was significantly higher in the 5-day remdesivir group and 10-day remdesivir group compared to standard care group (OR [95% confidence interval [CI]] =1.89 [1.40-2.56], P <0.001, OR [95% CI] =1.38 [1.15-1.66], P <0.001, respectively). In addition, the rate of clinical improvement was significantly higher in the 5-day remdesivir group compared to the 10-day remdesivir group (OR [95% confidence interval [CI]] =1.37 [1.01-1.85], P =0.041). Our analysis demonstrated that the use of remdesivir for patients with COVID-19 was associated with the significantly higher clinical improvement rate compared with standard care alone.

进行了几项随机对照试验（RCT），以研究瑞德昔韦对COVID-19患者的疗效，但结果相互矛盾。因此，我们进行了网络荟萃分析，比较接受5天疗程的伦德西韦与10天疗程的瑞姆昔韦与标准护理的COVID-19患者的临床改善率。我们对4项随机对照试验进行的网络荟萃分析表明，与标准护理组相比，在5天雷姆昔韦组和10天雷姆昔韦组的临床改善率显着更高（OR [95％置信区间[CI]] = 1.89 [1.40-2.56]，P <0.001，或[95％CI] = 1.38 [1.15-1.66]，P <0.001）。此外，与10天雷姆昔韦韦组相比，5天雷姆昔韦韦组的临床改善率显着更高（OR [95％置信区间[CI]] = 1.37 [1.01-1.85]，P = 0.041）。我们的分析表明，与单纯标准治疗相比，雷莫昔韦用于COVID-19的患者的临床改善率显着提高。